Welcome to the engineering conference call to discuss the company's third quarter 2025 financial results and share investigator-presented clinical case studies in pancreatic patients. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ensure that we have ample time to address everyone's question, we would like to ask each person to limit themselves to one question and one follow-up. As a reminder, this call is being recorded today, Wednesday, November 12, 2025. I would now like to turn the call conference over to Lawrence Watts of New Street Investor Relations.

Thank you, Operator. Joining us on the call today from engineering are Chief Executive Officer Ben Zeskin, Chief Scientific Officer Brett Hall, Chief Medical Officer Igor Machchensky, Chief Accounting Officer and Treasurer Amelia Morales, and E.B. Breakwood, our Chief Business Officer. During this call, management and a few investigators will refer to the slides that you can find in the updated version of our corporate deck available in PDF on our IR website. Throughout this call, management will be making forward-looking statements, including statements relates to its Phase 2A trial of a TETIMATNIP as well as the timing of additional data from the study and the company's development plans. Our actual results and the timing of events could differ materially from those anticipated in such forward-related statements as a result of risks and uncertainties. Factors that could cause these results to be different from these statements include factors the company describes in its security filings including its annual report on Form 10-K and our quarterly reports on Form 10-Q. undertakes no duty or obligation to update any forward listing statements as a result of new information, future events, or changes in its expectations. With that, I will turn the call over to Ben Zeskin, Chief Executive Officer of Immunearing.

Thank you, Lawrence. Good afternoon, everyone, and thank you for your interest in Immunearing. We do not always hold quarterly calls, but we try to do so when we have something interesting to share and today we are very fortunate to be joined by two investigators from our phase 2a trial who will walk us through two remarkable case studies of first-line pancreatic cancer patients treated with a tebimetinib in combination with fulfirinox the investigators are dr allison j ocean professor of clinical medicine at the weill medical college of cornell university and Dr. Gregory Bata, Associate Professor of Medicine at the Moores Cancer Center at UC San Diego. Doctors Ocean and Bata are, of course, busy individuals. We plan to start the call with their respective case studies, after which we will let them get back to their patients, and then we will share a summary of the third quarter and why it was so transformational for immune hearing. In September, we shared an update on 34 first-line pancreatic cancer patients treated with a tebimetinib in combination with gemcitabine napaclitaxel with remarkable overall survival. We're as excited as ever about the overall survival we are seeing in that cohort and we are very excited to share an update soon. We're currently planning to do so in the first half of 2026, possibly at a major medical meeting. Today, we wanted to talk about patients from a different arm of our study, a study of first-line pancreatic cancer patients treated with a tevimetinib in combination with fulfirinox. Fulfirinox is also a standard-of-care chemotherapy in the first-line setting. Compared with gemcitabine nabpaclitaxel, it has shown slightly longer survival in pivotal studies, but with harsher side effects. So it's typically given to younger, higher fitness patients at centers that are well-equipped to manage the harsher side effects. A tevimatinib in combination with gemcitabine nabpaclitaxel remains our top priority because the chemotherapy itself is so much better tolerated and the overall survival we have reported is so encouraging. That being said, down the road, the ability to combine a tevimatinib with fulfirinox may ultimately give oncologists more options. And certainly when we see remarkable outcomes in this cohort, it just lends further robustness to the data we have previously reported and highlights its heavy metanib's potential to drive differentiated outcomes for cancer patients. With that introduction, let me hand the call over to Dr. Ocean, who will walk you through

the first case study. Thank you, Ben. My name is Dr. Allison Ocean, and I'm a medical oncologist and attending physician in gastrointestinal oncology at New York Presbyterian Hospital, Weill Cornell Medical Center. I am also an investigator in Immunearing's Phase 2A study of attendimetinib and an occasional paid consultant to Immunearing. In my career, I have treated a large number of pancreatic cancer patients, and I can assure you the unmet need here is vast. The case study I'm about to walk you through comes from the arm studying atetimetinib in combination with fulfirinox in first-line pancreatic cancer. So this case study involves a 71-year-old female patient with metastatic pancreatic cancer with a KRAS G12D mutation who is currently being treated with daily atetimetinib plus fulfirinox. Initially, she was unable to tolerate irena tecan, so her chemo now is essentially Folfax. The patient has now been on treatment for approximately five months and remains on treatment. The patient's target lesion, located in the liver, steadily reduced over the course of three scans to the point of being undetectable for an unconfirmed complete response. On the right, you see the combination of atrevimetinib with fulfirinox led to, at the first scan, an unconfirmed partial response with a 54% reduction in sum of longest diameters, and then that partial response confirmed with an 81% reduction in sum of longest diameters at the second scan. By the third and most recent scan, the patient had a 100% reduction in their sum of longest diameters. In other words, the lesion was rendered undetectable for a complete response that is technically considered unconfirmed until we see it repeat at a second scan. Importantly, the patient has seen improved quality of life, stable weight, and describes feeling extremely well. In fact, she tells me she has never felt better. This is not surprising because our institution's experience with a tebimetinib has generally been one of good tolerance in the trial patients. It is very unusual to see a complete response with chemotherapy alone in a non-BRCA-mutated adenocarcinoma patient like this one. So, I believe atebimetinib has made a real difference for this patient. Our institution has treated several patients in various arms of the atebimetinib trial, including the combination of atebimetinib with gemcitabine, nabpaclitaxel, and we are very excited that it is moving into a planned Phase III study. This is a huge area of unmet need, so potential advancements like this are even more meaningful. With that, let me hand things over to Dr. Bada, who will walk you through a second case study.

Thank you, Dr. Ocean. My name is Gregory Bada, and I'm a medical oncologist who specializes in treating solid tumor cancers of the gastrointestinal system at the University of California, San Diego. I'm also an investigator for Immunearing's Phase 2A study. In my career, I have also treated a large number of pancreatic cancer patients. The patient in this case studies, again, from the arm, studying atebimetanib in combination with fulfirinox in first-line pancreatic cancer patients. For this case study, the patient was a 61-year-old female patient with biopsy-confirmed metastatic pancreatic cancer to the lung and a confirmed KRAS-G12D mutation. The patient initially achieved an unconfirmed PARFOR response and then stabilized for about five to six months. During that time, the primary lesion in the pancreas continued to shrink, achieving a 56% reduction by around seven months. The patient's response made her a candidate for treatment with curative intent. The remaining primary lesion was irradiated, and then the patient underwent a Whipple procedure to remove the remaining pancreatic lesion and has now restarted treatment on a tebivetinib monotherapy in the post-surgical setting. At the time of this call, the patient has now been on a tebimetinib, either in combination or as a monotherapy, for over 14 months and has experienced great quality of life and stable weight, much like the patient Dr. Ocean spoke about. Let me take a moment to talk about how rare that sequence of events is. Patients are not typically eligible for surgery once their condition has turned metastatic. But in this case, combination and treatment with a tebimetinib and fulfirinox was deemed so successful that surgery, preceded by radiation, with curative intent was considered a viable option. I believe a tebimetinib helped us convert this patient to a surgical candidate with curative intent, an outcome that I have rarely seen with chemotherapy alone. And today, the patient has no radiologic evidence of new disease. Now, while the patient has to be censored from survival measurements, the patient continues to do well approximately 14 months after starting treatment and remains on a tebimetinib monotherapy treatment. Our site has also treated many other patients with a tebimetinib, and we have seen other responses that would be unexpected with chemotherapy alone. A tebimetinib's tolerability is also unexpectedly good, even relative to RAS inhibitors. We are very excited for the planned phase 3 study of the tebimetinib in combination with gemcitabine and apaclitaxel. And with that, let me hand the call back over to Ben.

Thank you, Dr. Bada. Let me take this opportunity to thank both you and Dr. Ocean for taking time out of your busy schedules to join us and provide your insight. We're very grateful to have both of you involved in our ongoing studies and for everything that you do every day for patients with cancer. And with that, we'll let you get back to your important work. What I take from the two case studies just presented is several-fold. Firstly, that these impressive results we are seeing for a tebimetinib in combination with fulferinox provide another pillar of robustness supporting the extraordinary overall survival we presented for a tebimetinib plus modified gemcitabinab paclitaxel in September. Secondly, that patient's dose with a tebimetinib plus fulferinox could potentially provide additional optionality alongside our top priority planned pivotal program for a tebimetinib plus modified gemcitabine nabtaclitaxel. Thirdly, we believe the tolerability of a tebimetinib is going to be a real differentiator. Of course, the most important differentiator is extraordinary overall survival. And when you layer onto that Dr. Bada saying a patient has experienced great quality of life and Dr. Ocean saying her patient has never felt better, it really gives you a sense of what we mean when we say we want to keep patients alive and help them thrive. These patients are clearly thriving, and we couldn't be happier for them. Now, let me take a step back and just recap why the third quarter of 2025 was truly transformational for immuneering. In September, we announced extraordinary overall survival data in 34 first-line pancreatic cancer patients treated with a tebimatinib in combination with gemcitabine nabpacotaxel and strengthened our balance sheet with $225 million of cumulative financing, including a $25 million strategic investment from Sanofi. Importantly, these achievements extend our cash runway into 2029 and fund the top-line readout of our planned pivotal program for atabumetinib plus modified gencitabine napaclitaxel, along with our clinical work in lung cancer and preclinical work in other areas. In September, we reported 86% overall survival at nine months in 34 first-line pancreatic cancer patients treated with a tebumetinib plus modified gemcitabine nabpacotaxel with a nine month median follow-up. For context, the standard of care reports approximately 47% overall survival in nine months. We are excited to share an update on a tebumetinib in combination with gemcitabine nabpacotaxel and currently plan to do so in the first half of 2026, possibly at a major medical meetings. We also made progress across a number of other fronts in the third quarter. In July, the U.S. Patent Office granted our U.S. Composition of Matter patent for its heavy metinib, which is expected to provide exclusivity into 2042 with potential eligibility for patent term extension. We have patent applications pending that extend exclusivity until late 2044. Then, in August, we announced a clinical supply agreement with Eli Lilly intended to evaluate atevimatinib in combination with olomiracid, a second-generation KRAS G12C inhibitor, in a planned phase 2A trial in lung cancer patients who have progressed on prior therapy. Remember that earlier this year, we also announced a clinical trial agreement with Regeneron, intended to evaluate atevimetinib in combination with libtio, an anti-TD1 inhibitor in advanced lung cancer. Together, we believe these agreements position us to demonstrate atevimetinib's combinability across a variety of tumor types, potentially expanding its market opportunity beyond the already considerable unmet need in first-line pancreatic cancer. It's heavy men's durability and tolerability make it ideal for a wide variety of combinations across many different types of cancer. Before I cover the multitude of catalysts we believe we have coming up, let me quickly turn things over to Mallory to walk you through our third quarter financial update.

Thank you, Ben. Our third quarter financial results press release, issued post-market this afternoon, covers our financial results in detail, so I will not go through them at length on this call. What I will highlight, however, is our significantly improved cash position, which was bolstered by three successful offerings that took place in August and September, namely, a $25 million private placement in August, a $175 million underwritten offering of Class A common stock in September, coupled with a $25 million private placement of Class A common stock to Sanofi. As a result, our cash and cash equivalents as of September 30, 2025 were $227.6 million, compared with $36.1 million as of December 31, 2024. Based on management's current operating plans, The company now expects its cash runway to be sufficient to fund operations into 2029. With that, let me hand the call back over to Ben.

Thank you, Mallory.

In terms of upcoming near-term milestones, in the fourth quarter of 2025, we expect feedback from regulatory agencies and continued preparations to begin dosing patients in the pivotal trial of atevimetinib in combination with gemcitabine nabpaclitaxel in first-line pancreatic cancer patients. In the second quarter of 2026, we plan to announce updated circulating tumor DNA data on acquired alterations at a major scientific meeting. In the first half of 2026, we plan to report updated survival data from first-line pancreatic cancer patients treated with atevimetinib plus modified gemcitabine nabpaclitaxel, potentially at a major medical meeting. In mid-2026, we expect to dose the first patient in the pivotal phase 3 trial of atevimetinib in combination with modified gemcitabine nabpaclitaxel in first-line pancreatic cancer, pending regulatory feedback. And in the second half of 2026, we expect to dose the first patient in the trial of atevimetinib in combination with libtio in non-small cell lung cancer. Our third quarter press release includes a detailed list of the near-term catalysts we have coming up, each one an opportunity to create value for our shareholders, and each one a step forward in helping patients live longer and feel better. Coming out of the third quarter, we have never been better capitalized, nor have we ever had more evidence of its heavy batonib's ability to shrink tumors slowly and surely with remarkable durability and tolerability. In summary, then, I could not be more proud of the benefits we're delivering for patients, and I could not be more excited about what the coming weeks and months will bring for immuneering. With that, we're happy to take questions.

Operator. Thank you. And we will now begin the question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad to join the queue. If you would like to withdraw your question, simply press star 1 again. If you're called upon to ask your question and are listening by a loudspeaker on your device, please pick up your handset and ensure that your phone is not on mute when asking your question. Just a reminder, we ask that you please limit yourself to one question and one follow-up only. And after that, you can just simply join the queue again. Thank you. And your first question comes from Jay Olson from Oppenheimer. Please go ahead.

Oh, hey, guys. Congrats on all the progress, and thank you for providing this update. We had a couple questions to start. Can you talk about, based on these new case studies and the plane safety profile for Tebby, Are you considering opportunities for PDAC in the adjuvant setting? And then we had a follow-up if we could.

Thanks for the question. You know, right now our top priority is the first-line setting and the combination of a tevimetinib with the modified gemcitabine, that paclitaxel. I mean, I think the overall survival that we announced in September, 86% overall survival at nine months, is just so remarkable. and the tolerability that we saw with only two categories of adverse events at the grade three level and more than 10% of the patients. So that's really our top priority, but I think you're absolutely right. There's a wide range of potential opportunities kind of down the road a little bit, and certainly adjuvant is one that we're thinking carefully about among others. So no decisions to report there today. But certainly, I think you're absolutely right. There's a lot of potential in a lot of different areas. And, you know, I think first-line pancreatic cancer is really just the beginning for a tevimetinib. But it's, you know, it's our top priority and it's

a place we're going to start. Okay. Understood. Thank you for that. And maybe just to follow-up, recognizing that you're prioritizing the combo of a TEVI with GEM-NABPAC. Given these new case studies and, again, the clean safety, would you consider potentially combining a TEVI with 5-FU-based regimens?

Yeah, it's absolutely something that we're thinking about, Jay, for all the reasons you pointed out. You know, again, it's not currently our top priority. The top priority certainly remains the atabimatinib combination with the modified gemcitabine natpaclitaxel in first-line pancreatic cancer, just because, you know, we see such exciting overall survival there. But we're, you know, I think part of the reason for sharing these cases today, number one, they kind of further validate the data that we presented with gemcitabine napaclitaxel in September. They show that we can combine with fulfirinox, which not everyone can. And I think to your point, that certainly demonstrates the potential for greater optionality down the road. So it's certainly something that we're thinking about and considering. And I think these cases also really emphasize what a differentiator tolerability is for a tabimetinib, right? I mean, you heard Dr. Bada saying his patient has experienced great quality of life. You heard Dr. Ocean saying her patient has never felt better. And so I think that does really give you a sense of the tolerability and, you know, it creates a lot of potential options down the road, whether it's combining with fulfirinox, going into the adjuvant setting and many more. So you're absolutely right. There's a lot of possibilities for that. But our top priority remains the first line setting in combination with

gemcitabine, napaclitaxel. Okay, thank you. That makes perfect sense. Maybe if I could sneak in one last question. Sure. Just based on the totality of data that you've shared so far and the differentiated profile for a TEBI that's emerged, can you just update us on your latest thoughts about where Tabi fits into the competitive landscape in PDAC? Yeah, I think the

overall survival that we shared in the first line setting is extraordinary, right? I mean, you know, and look, we welcome every company that's working in pancreatic cancer. This is a huge unmet need that's not going to be solved by any one company alone. But certainly we believe we're the company that's going to solve it first and best in the first-line setting, right? There's, you know, there's not another company working in this pathway that we're aware of that's shared first-line overall survival data. And first-line is the real prize in pancreatic cancer because sadly, half the patients don't make it out of the first-line setting. So we really hear over and over from ontologists that your first shot is your best shot And first-line pancreatic cancer is the real prize here. We're the only company in this pathway that we're aware of that shared overall survival data in the first-line setting. I think our overall survival data is extraordinary. I mean, to have 86% overall survival at nine months in the data we shared in September, that's a 39-point separation from the pivotal study of standard-of-care gemcitabine, napaclitaxel. So we believe that that kind of overall survival is going to be hard to beat. There's just not a lot of room above that curve to decisively beat it. And to the extent another company could match it, and we certainly don't know of anyone that we think could, but if to the extent another company could match it, then I think it would come down to tolerability. And I think we show clear differentiation on tolerability, certainly from, you know, from anything else in this pathway, right? And, I mean, I think you heard Dr. Bada say that directly, you know, kind of unexpectedly good tolerability even relative to RAS inhibitors. So, you know, I think we're the frontrunners in first line. You know, we've shared survival data. That's the gold standard. That's what matters most. And, you know, we don't think anyone's going to beat that. And even if they could match it, we think we'd win on tolerability. So we feel very good about where we sit in the competitive landscape.

Congrats again on all the progress, and thanks for taking the questions.

Thank you, Jay.

And your next question comes from Andrew Behrens from E-Muneering. Please go ahead.

Hi. This is Emily on for Andy from Leering. So, yeah, congrats on the data and those case studies. I guess I'm kind of curious, do you have any plans to share the full data from that full Cironox combination cohort in the near term? And then, you know, sort of looking ahead, if this data from that cohort continues to look robust, do you have any plans to try and get a compendial listing for this combination so it could be potentially, you know, used and reimbursed in the future? Thank you.

Yeah. Hey, Emily, great question. and certainly you and Andy are affiliated with Lyrinc. I think I appreciate immunization, but we're not breaking any news on that today. You and Andy work for Lyrinc, but just joking around. You know, I think the, yeah, we're not guiding to timing yet in terms of when we might share data from the Fulferinox arm because it's just currently not our top priority, right? Our top priority is first-line pancreatic cancer in combination with gemcitabine, nampacotaxel, where we're just seeing this extraordinary 86% overall survival in nine months in the data we announced in September. So, that's the top priority. But, you know, I think what we shared today certainly further validates those data we shared in September. You know, I think it really creates a lot of additional optionality for us that we, you know, we can combine with Fulfirinox and we can see these remarkable outcomes. So, you know, we're still, you know, still considering that relative to everything else. So certainly can't guide on that today. But it's, you know, it's great to see how well these patients are doing and, you know, great to hear Dr. Vata and Dr. Ocean talking about how truly rare these kind of outcomes are with chemotherapy alone. I mean, to have a complete response in pancreatic cancer is just remarkable. And to, I mean, to be able to have a patient that can go on from metastatic disease to be able to go on to surgery with curative intent, these are really just exciting outcomes and we're really happy about them.

So, yeah, very exciting.

Thanks so much.

Thank you, Emily.

And your next question comes from Greg Sivanavaj.

from Measle. Please go ahead. Hi. Good afternoon. Thanks for taking my questions. And congrats on the newer data as well. I was curious, given that you've provided some timing with regards to a new study with your combination with Regeneron and Liptio, that I think the comment was you'd be able to start that sometime in the second half of 2026. given that you also have a very interesting collaboration with Lily two questions one, do you think based on what you know today whether that study too can get started in 2026 or do you think that's more of a 2027 timeline and then also related how do you see on the assumption that they're both going into non-small cell lung cancer, how do you see kind of the differential positioning between those two combinations? And then the last question is with regards to your cash runway, which is out to 2029, and congrats on the success with the financings. But what are you particularly or specifically funded for in terms of clinical development, clinical trials, pipeline advancement, just trying to get a sense of what you're currently funded for? Thanks.

Hey, Greg. Thanks for the questions. We appreciate it. So, you're absolutely right. We, you know, we gave new guidance today on the timing of the study of atevimetinib in combination with Regeneron's anti-PD-1 libtio in lung cancer. And we said not just, I think you used the word start, but we specifically said we're going to dose the first patient in the second half of 2026. And, you know, I think that's important. Different companies use kind of ambiguous words that can mean, really mean very different things around trial timing. But dosing the first patient is just a really clear and unambiguous milestone. So, you know, that's why we're, you know, we like to be clear with that. So absolutely dosing the first patient in that study in the second half of 2026. And we're really excited about that because of all the preclinical data, both from us and from real luminaries in the immunotherapy field, like Jed Walchuk, who has a paper showing that pulsatile inhibition of MEK can really enhance the activity of immunotherapy in a lung cancer model in a preclinical setting. So really, really excited about that study and looking forward to dosing that first patient. With regard to our agreement with Eli Lilly to evaluate Tevimatinib in combination with olomoracid, you'll recall we, you know, that agreement is much more recent, right? So while we had announced a Regeneron agreement in February, that one we announced over the summer, towards the end of the summer. So, it's just a little early to guide on that yet. So, we're just not going to guide on the timing of the first patient dose, but certainly in due time, you can expect guidance on that. You know, in terms of the kind of the dynamic between those two, look, I mean, you know, there's, again, a vast unmet need in lung cancer. You know, obviously, the olumiracid is a KRAS G12C inhibitor, so that trial would be focused on patients with a KRAS G12C mutation, whereas, you know, the use of immunotherapy would potentially address, you know, a different population of patients. So, you know, I think it's early to really comment further on that. But I will, you know, I will say we think it's heavy metinib with its ability to durably inhibit the MAP kinase pathway with this really kind of excellent tolerability that I think you just heard about from two of the investigators. You know, we think it's really an attractive backbone, frankly, for combinations with a wide variety of agents. And, you know, we've shared preclinical data on quite a few and are exploring quite a few more. So there's just really a broad potential for combinations here. And we don't, you know, we think of these two as kind of just the beginning of the potential for a tevimetinib. heavy metinib. So, just really excited for what we'll be able to do for patients with, you know, what we believe we'll be able to do for patients with lung cancer, colorectal cancer, melanoma, just a really vast number of types of cancer that are frequently driven by the MAP kinase pathway. So, really excited about the breadth there. And then, you know, with regard to our cash guidance with Runway into 2029, you know, we're certainly funded to conduct the phase three as we've laid out to conduct these, you know, these studies in lung cancer and then to, you know, to advance our preclinical pipeline as well, right? So, keep in mind that, you know, atevimetinib is the first and most advanced of our pipeline of deep cyclic inhibitors, but we're pursuing and developing deep cyclic inhibitors against a variety of targets in oncology and a variety of pathways. So, we're, you know, we're certainly excited to continue that work because I think the, you know, the ability that Atavimetinib has demonstrated of deep cyclic inhibitors to, you know, to mitigate resistance mechanisms, to durably inhibit tumors and to do so with just just really remarkable tolerability. I mean, to hear a cancer patient say they've never felt better, as Dr. Roshan mentioned, is just really remarkable. So, we're excited for that

preclinical pipeline as well. Thank you, Greg. And your next question comes from Ami Fadia from Needham and Company. Please go ahead. Thanks. Good evening. I have a couple

questions. Firstly, you know, based on the data that we've seen so far with the combinations with Folfuri and GenMapPack, given the team safety profile of ATEBI, what type of patients would you consider, you know, as being best suited for the combination with Folfuri instead of GenMapPack? And then, you know, I think as we sort of think about the first-line PDAC positioning, you know, how do you see the safety profile translating into the durability of benefit? And, you know, you mentioned earlier that you're going to be presenting some additional circulating DNA data next year. next year, if you could sort of talk to how, you know, what you've learned from the ctDNA analysis so far and how that might contribute to the overall durability of benefit, particularly in

the first-line setting. Thank you. Yeah, thanks, Ami. Great questions. So, you're right. Certainly, you know, I think we've demonstrated clearly the ability to combine with Ulfirinox, with gemcitabine, napaclitaxel, and with a clean safety profile in first-line pancreatic cancer patients. And we think that really, you know, that really means that tabimatinib could help a really broad set of patients in the first-line setting in pancreatic cancer. And in fact, one of the things that's nice about our trial is, you know, we don't have to do any genetic testing, right? So that, you know, there have been trials of, say, RAS inhibitors where they, you know, they have to confirm the presence of a RAS mutation. And we just haven't, we don't need to do that because atevimatinib targets MEK, which is further downstream in the pathway. And so, you know, it blocks a wide variety of mutations that drive this pathway.

And I think that's important for durability because, again, you know, with RAS inhibitors,

and maybe this is a good segue to your next question, you know, with RAS inhibitors, you know, you often see resistance mechanisms. You know, you see with RAS inhibitors progression that can sometimes come from, say, KRAS amplifications or BRAF mutations. That's been reported to be common. And, you know, atavimetinib being further downstream at MEC, you know, it blocks those kind of mechanisms, right? So the, you know, the acquired alteration data that we've shared previously that's in our public deck, you know, we saw no acquired alterations in RAS genes and very few in the MAP kinase pathway at all. So what this tells us is, you know, a tebimatinib is effectively blocking all the lanes of the highway, if you will. It's, you know, it's blocking a lot of the MAP kinase pathway, and it's just, it's very hard for the tumor to get around atevimetinib using the MAP kinase pathway. And that's just not the case for RAS inhibitors based on the data that's out there. So, you know, I think that alone, by virtue of the target, lends durability. And then, of course, the fact that atevimetinib is a deep cyclic inhibitor and has this pulsatile mechanism, you know, I think that also really helps to mitigate resistance, right? Because instead of providing the tumor with just a steady, constant signal that frankly makes it easy for the tumor to adapt, you know, we have this pulsatile approach where we hit the tumor very hard and then release. And that, you know, it basically keeps the tumor off balance, if you will. It makes it harder for the tumor to adapt and get around the treatment. And this, you know, this was a design goal from the very beginning, right? I mean, we started this company around the goal of driving overall survival. And so, you know, things like mitigating resistance, things like tolerability, like counteracting muscle wasting. I mean, these were the priorities from the beginning. And, you know, I think that's why we really developed this differentiated class in deep cigarette inhibitors and why we're seeing such differentiated survival, like the 86% overall survival at nine months and the atevimatinib in combination with gemcitabine, napaclitaxel that we announced in September.

So with that, thank you. Yeah. Next question.

There are no further questions at this time. And now I would like to turn the call back over to Ben Zeskin for the closing remarks. Please go ahead.

Well, I want to thank everyone for joining our call today. And we'd particularly like to thank all the patients and investigators involved in our ongoing studies. And we very much look forward to updating everyone on our future progress. Thank you, everyone.